NuCana Q2 FY26 net loss narrows to £3.08 million; operating loss shrinks to £3.55 million

Reuters2026/08/13 20:01

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

NuCana posted a net loss of £3.1 million for Q2 2026, narrowing from a £24.1 million loss a year earlier.
Operating loss narrowed to £3.55 million from £11.83 million, while R&D expense fell to £2.25 million from £7.1 million.
Cash and cash equivalents slipped to £19.5 million at June 30 from £24.3 million at Dec. 31, 2025.
Recruitment completed in NuTide:701 Phase 2 expansion of NUC-7738 with Keytruda in PD-1 inhibitor-resistant metastatic melanoma; final data still slated for 2026.
Cash runway expected to extend into 2029; FDA dialogue ongoing on a potential registrational strategy for NUC-7738 in melanoma.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NuCana plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608131601OMX_____CNEWS_EN_GNW9809563_en) on August 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

NuCana Q2 FY26 net loss narrows to £3.08 million; operating loss shrinks to £3.55 million

You may also like

Crypto prices